Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319244 | 0.96 | KCNH2 (0.77) | KCNH2 | |
| SCHEMBL6320177 | 0.93 | KCNH2 (0.67) | KCNH2 | |
| SCHEMBL6324169 | 0.90 | KCNH2 (0.66) | KCNH2 | |
| SCHEMBL6318147 | 0.89 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL6317868 | 0.88 | KCNH2 (0.90) | KCNH2 | |
| SCHEMBL6317282 | 0.88 | KCNH2 (0.88) | KCNH2 | |
| SCHEMBL6325902 | 0.88 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL6318883 | 0.87 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6319832 | 0.87 | KCNH2 (0.79) | KCNH2 | |
| SCHEMBL6318778 | 0.86 | KCNH2 (0.83) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| US-6960573-B2 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-6867313-B2 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-6689766-B2 | ALSO FOR TREATING MALIGNANT TUMORS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, DIABETES MELLITUS, HYPERTENSION, ALOPECIA, ACNE, PSORIASIS, DERMATITIS, HYPERCALCEMIA, HYPOPARATHYROIDISM AND METABOLIC DISORDER OF CARTILAGE. | TEIJIN LIMITED (JP) | 2004-02-10 | — | — | US | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6548489-B2 | Also for treating malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage. | TEIJIN LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531460-B1 | Vitamin D3 derivatives | TEIJIN LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-08-01 | — | — | US | disclosed |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | KCNH2 2747/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KCNH2 491/4885 |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | KCNH2 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.